Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | CALML3 | P27482 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411603 | 0.91 | CALML3 (0.50) | CALML3CYP2C9CYP2C19MAOAMAOB | |
| SCHEMBL411607 | 0.89 | CYP2C19 (0.41) | CALML3CYP2C9CYP2C19MAOAMAOB | |
| SCHEMBL412043 | 0.87 | CALML3 (0.48) | F10CALML3CYP2C9CYP2C19MAOA | |
| SCHEMBL411600 | 0.85 | F10 (0.44) | F10GRM2GRM5MAOAMAOB | |
| SCHEMBL412061 | 0.84 | F10 (0.45) | F10GRM2GRM5MAOAMAOB | |
| SCHEMBL411159 | 0.84 | TDO2 (0.39) | F10GRM2GRM5CALML3CYP2C9 | |
| SCHEMBL411610 | 0.83 | GRM2 (0.37) | F10GRM2GRM5CALML3CYP2C9 | |
| SCHEMBL412641 | 0.83 | GRM5 (0.42) | GRM2GRM5CALML3MAOAMAOB | |
| SCHEMBL412829 | 0.78 | CALML3 (0.53) | CALML3CYP2C9CYP2C19MAOAMAOB | |
| SCHEMBL411105 | 0.78 | CALML3 (0.51) | CALML3CYP2C9CYP2C19MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | F10 3187/4885GRM2 4861/4885GRM5 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.